Agentix (AGTX) Change in Account Payables (2014 - 2026)
Agentix's (AGTX) quarterly Change in Account Payables came in at $91885.0 in Q1 2026, up 3.63% YoY from $88669.0 in Q1 2025, and up 30.04% on a QoQ basis from $70657.0 in Q4 2025.
Agentix (AGTX) Change in Account Payables (2014 - 2026) Analysis & Trends
Agentix (AGTX) has 12 years of Change in Account Payables data on file, last reported at $91885.0 in Q1 2026.
- Quarterly Change in Account Payables rose 3.63% year-over-year to $91885.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $301913.0 (down 31.06% YoY) and the FY2026 annual result came in at $301913.0, down 31.06% from the prior year.
- Change in Account Payables advanced to $91885.0 in Q1 2026, from $70657.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $422418.0 in Q2 2023 to a low of -$334333.0 in Q1 2024.
- A 5-year average of $105601.6 and a median of $97837.0 in 2024 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2023 — Change in Account Payables jumped 164.51% — and 2024, when it tumbled 6687.84%.
- Tracing AGTX's Change in Account Payables over 5 years: stood at $350128.0 in 2022, then plunged by 168.9% to -$241238.0 in 2023, then jumped by 116.22% to $39118.0 in 2024, then surged by 80.63% to $70657.0 in 2025, then soared by 30.04% to $91885.0 in 2026.
- The last three Change in Account Payables figures came in at $91885.0 (Q1 2026), $70657.0 (Q4 2025), and $167715.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Agentix | 801,339.00 | 801,301.00 | - | 91,301.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91,301.00 |
| Jun 30, 2026 | 91,301.00 |
| Mar 31, 2026 | 91,885.00 |
| Mar 31, 2026 | 91,885.00 |
| Dec 31, 2025 | 70,657.00 |
| Dec 31, 2025 | 70,657.00 |
| Sep 30, 2025 | 167,715.00 |
| Sep 30, 2025 | 167,715.00 |
| Jun 30, 2025 | -28,344.00 |
| Jun 30, 2025 | -28,344.00 |
| Mar 31, 2025 | 88,669.00 |
| Mar 31, 2025 | 88,669.00 |
| Dec 31, 2024 | 39,118.00 |
| Dec 31, 2024 | 39,118.00 |
| Sep 30, 2024 | 103,789.00 |
| Sep 30, 2024 | 103,789.00 |
| Jun 30, 2024 | 206,353.00 |
| Jun 30, 2024 | 206,353.00 |
| Mar 31, 2024 | -334,333.00 |
| Mar 31, 2024 | -334,333.00 |